-+ 0.00%
-+ 0.00%
-+ 0.00%

Palisade Bio wins FDA IND clearance for PALI-2108 Crohn’s disease Phase 2 trial

PUBT·09/22/2026 12:35:27
Listen to the news
Palisade Bio wins FDA IND clearance for PALI-2108 Crohn’s disease Phase 2 trial
  • Palisade Bio received FDA clearance of its IND for PALI-2108, enabling a Phase 2 trial in moderate to severe Crohn’s disease.
  • ASCENTRA-CD is set to enroll about 60 patients; first dosing targeted for Q1 2027.
  • Primary efficacy readout targeted for Q1 2028, based on Week 12 endoscopic response.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palisade Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609220835PRIMZONEFULLFEED9831033) on September 22, 2026, and is solely responsible for the information contained therein.